The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Engraftment syndrome following ASCT in patients with checkpoint inhibitor treated Hodgkin lymphoma
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses a multi-center retrospective analysis which aimed to investigate the frequency and management of engraftment syndrome during autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL) who were treated with checkpoint inhibitors. Dr Svoboda outlines the findings of the study, highlighting that steroids were found to be effective for the management of this adverse event. He also emphasizes the need for the development of a better definition of engraftment syndrome, which will aid clinicians in its diagnosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: TG Therapeutics, BMS, SEAGEN, Pharmacyclics, Adaptive, Incyte, Astra Zeneca, Merck
Consultancy: BMS, ADCT, SEAGEN, Pharmacyclics, Atara, Adaptive, Incyte, Astra Zeneca, Genmab
